-SEC Filing
Unicycive Issued Notice Of Acceptance To Initiate Phase 1 Study Of UNI-494 Following Review Of Clinical Trial Application By The Medicines And Healthcare Products Regulatory Agency In The United Kingdom
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, announced today that the Medicines and Healthcare Products Regulatory Agency